|
Volumn 27, Issue 5, 2001, Pages 338-343
|
Are antipsychotic drugs the right treatment for challenging behaviour in learning disability?: The place of a randomised trial
a a a a |
Author keywords
Antipsychotic medication; Challenging behaviour; Learning disability; Randomised trial; Research ethics
|
Indexed keywords
NEUROLEPTIC AGENT;
THIORIDAZINE;
ARTICLE;
BEHAVIOR DISORDER;
CAREGIVER;
CLINICAL STUDY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG SAFETY;
DRUG USE;
EVIDENCE BASED MEDICINE;
HUMAN;
INFORMED CONSENT;
LAW SUIT;
LEARNING DISORDER;
LONG TERM CARE;
MEDICAL ETHICS;
MEDICAL RESEARCH;
METHODOLOGY;
MORALITY;
RANDOMIZED CONTROLLED TRIAL;
RISK BENEFIT ANALYSIS;
TARDIVE DYSKINESIA;
WELLBEING;
BEHAVIOR CONTROL;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
MENTAL HEALTH THERAPIES;
RESEARCH ETHICS;
RISKS AND BENEFITS;
ANTIPSYCHOTIC AGENTS;
BEHAVIOR CONTROL;
DOUBLE-BLIND METHOD;
ETHICS, CLINICAL;
ETHICS, RESEARCH;
GREAT BRITAIN;
HUMAN EXPERIMENTATION;
HUMANS;
LEARNING DISORDERS;
MENTAL DISORDERS;
MULTICENTER STUDIES;
PLACEBOS;
RANDOMIZED CONTROLLED TRIALS;
RISK ASSESSMENT;
|
EID: 0034794359
PISSN: 03066800
EISSN: None
Source Type: Journal
DOI: 10.1136/jme.27.5.338 Document Type: Article |
Times cited : (14)
|
References (24)
|